# US 2010/0168187 A1 · Therapeutic combination

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168187 A1
- Document ID: US20100168187A1
- Status: Published application
- Kind: A1
- Application number: 12/721,065
- Filed: 2010-03-10
- Published: 2010-07-01
- Earliest claimed: 1997-08-29
- Inventors: Jan Buch
- Web page: https://patentgrep.com/patent/US20100168187A1

## CPC

- A61K 31/4422: 1,4-Dihydropyridines, e.g. nifedipine, nicardipine
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/435: having six-membered rings with one nitrogen as the only ring hetero atom
- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61P 3/06: Antihyperlipidemics
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 11/06: Antiasthmatics
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/40: Cyclodextrins; Derivatives thereof
- A61K 2039/55577: {Saponins; Quil A; QS21; ISCOMS}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

This invention relates to pharmaceutical combinations of amlodipine or a pharmaceutically acceptable acid addition salt thereof and atorvastatin or a pharmaceutically acceptable salt thereof, kits containing such combinations and methods of using such combinations to treat subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and to treat subjects presenting with symptoms of cardiac risk, including humans. This invention also relates to additive and synergistic combinations of amlodipine and atorvastatin whereby those synergistic combinations are useful in treating subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and those subjects presenting with symptoms of cardiac risk, including humans.

## Claims

### Claim 1

A single pharmaceutical composition comprising:
an amount of amlodipine or a pharmaceutically acceptable acid addition salt thereof;
an amount of atorvastatin or a pharmaceutically acceptable salt thereof; and
a pharmaceutically acceptable carrier or diluent.

### Claim 2 (depends on 1)

A pharmaceutical composition of claim 1 comprising amlodipine besylate.

### Claim 3 (depends on 2)

A pharmaceutical composition of claim 2 comprising the hemicalcium salt of atorvastatin.

### Claim at position 4

4-117. (canceled)

### Claim 118 (depends on 1)

The pharmaceutical composition of claim 1 comprising the hemicalcium salt of atorvastatin.

### Claim 119 (depends on 1)

The pharmaceutical composition of claim 1 wherein said atorvastatin is present in an amount from about 2.5 mg to about 160 mg.

### Claim 120 (depends on 1)

The pharmaceutical composition of claim 1 wherein said atorvastatin is present in an amount from about 10 mg to about 80 mg.

### Claim 121 (depends on 2)

The pharmaceutical composition of claim 2 wherein said amlodipine besylate is present in an amount from about 2.5 mg to about 20 mg.

### Claim 122 (depends on 2)

The pharmaceutical composition of claim 2 wherein said amlodipine besylate is present in an amount from about 5 mg to about 10 mg.

### Claim 123 (depends on 2)

The pharmaceutical composition of claim 2 wherein said atorvastatin is present in an amount from about 2.5 mg to about 160 mg and said amlodipine besylate is present in an amount from about 2.5 mg to about 20 mg.

### Claim 124 (depends on 3)

The pharmaceutical composition of claim 3 wherein said hemicalcium salt of atorvastatin is present in an amount from about 2.5 mg to about 160 mg.

### Claim 125 (depends on 3)

The pharmaceutical composition of claim 3 wherein said hemicalcium salt of atorvastatin is present in an amount from about 10 mg to about 80 mg.

### Claim 126 (depends on 3)

The pharmaceutical composition of claim 3 wherein said hemicalcium salt of atorvastatin is present in an amount from about 2.5 mg to about 160 mg and said amlodipine besylate is present in an amount from about 2.5 mg to about 20 mg.

### Claim 127 (depends on 3)

The pharmaceutical composition of claim 3 wherein said hemicalcium salt of atorvastatin is present in an amount from about 10 mg to about 80 mg and said amlodipine besylate is present in an amount from about 5 mg to about 10 mg.

### Claim 128 (depends on 1)

The pharmaceutical composition of claim 1 wherein said amlodipine or said pharmaceutically acceptable acid addition salt thereof occurs as a hydrate or a solvate.

### Claim 129 (depends on 1)

The pharmaceutical composition of claim 1 wherein said atorvastatin or said pharmaceutically acceptable acid addition salt thereof occurs as a hydrate or a solvate.

### Claim 130 (depends on 1)

The pharmaceutical composition of claim 1 wherein said pharmaceutical composition is in the form of a tablet and comprises at least one excipient, at least one disintegrant, and at least one binding agent.

### Claim 131 (depends on 130)

The pharmaceutical composition of claim 130 wherein said excipient is selected from the group consisting of sodium citrate, calcium carbonate, and calcium phosphate.

### Claim 132 (depends on 130)

The pharmaceutical composition of claim 130 wherein said disintegrant is potato starch or tapioca starch.

### Claim 133 (depends on 130)

A pharmaceutical composition of claim 130 wherein said binding agent is selected from the group consisting of polyvinylpyrrolidone, sucrose, gelatin, and acacia.

### Claim 134 (depends on 130)

A pharmaceutical composition of claim 130 wherein said tablet comprises at least one lubricating agent.

### Claim 135 (depends on 1)

The pharmaceutical composition of claim 1 further comprising an excipient.

### Claim 136 (depends on 135)

The pharmaceutical composition of claim 135 wherein the excipient is calcium carbonate.

### Claim 137 (depends on 1)

The pharmaceutical composition of claim 1 further comprising a disintegrant.

### Claim 138 (depends on 137)

The pharmaceutical composition of claim 137 wherein the disintegrant is starch.

### Claim 139 (depends on 1)

A pharmaceutical composition of claim 1 wherein said pharmaceutical composition is in the form of an aqueous suspension and comprises at least one sweetening agent, at least one flavoring agent, at least one coloring agent, at least one emulsifying agent, and at least one suspending agent.

### Claim 140 (depends on 135)

A pharmaceutical composition of claim 135 wherein said diluent is selected from the group consisting of water, ethanol, propylene glycol, and glycerin.

### Claim 141 (depends on 1)

A pharmaceutical composition of claim 1 in a form suitable for oral administration comprising a solution, suspension, tablet, pill, capsule or powder containing atorvastatin or a pharmaceutically acceptable salt thereof in an amount from about 2.5 mg to about 160 mg and amlodipine or a pharmaceutically acceptable acid addition salt thereof in an amount from about 2.5 mg to about 20 mg.

### Claim 142 (depends on 137)

A pharmaceutical composition of claim 137 containing from about 5 mg to about 10 mg amlodipine besylate and from about 10 mg to about 80 mg of the hemicalcium salt of atorvastatin.

### Claim 143 (depends on 1)

A pharmaceutical composition of claim 1 in the form of a tablet containing from about 5 mg to about 10 mg amlodipine besylate, from about 10 mg to about 80 mg of the hemicalcium salt of atorvastatin, at least one excipient, at least one disintegrant, at least one lubricating agent and at least one binding agent.

### Claim 144 (depends on 139)

A pharmaceutical composition of claim 139 in the form of a controlled release formulation.

### Claim 145 (depends on 1)

The pharmaceutical composition of claim 1 comprising amlodipine mesylate.

### Claim 146 (depends on 1)

The pharmaceutical composition of claim 1 comprising amlodipine maleate.

### Claim 147 (depends on 1)

The pharmaceutical composition of claim 1 comprising amlodipine tosylate.
